RNA, U1 small nuclear 63, pseudogeneGenealiases: []
Q-omics provides the consensus-scored RNU1-63P profile across patient tissues and cancer cell-line models. RNU1-63P expression is associated with patient survival in 12 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, RNU1-63P is differentially expressed in 4, with the highest sampling consensus in THCA. Additionally, RNU1-63P RNA expression shows 7,103 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight BLCA, THCA, and HNSC as cancer lineages where RNU1-63P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNU1-63P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNU1-63P survival associations across molecular data types. RNU1-63P RNA expression shows survival associations in the most cancer types (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNU1-63P RNA expression–survival associations across cancer types. High RNU1-63P expression shows unfavorable associations in BLCA, LUAD, TGCT, UVM, LIHC and STAD. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for RNU1-63P RNA expression.
This table summarizes RNU1-63P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for RNU1-63P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNU1-63P shows lower tumor expression in THCA and LUSC and higher tumor expression in KIRC and LIHC. The THCA box plot shows higher RNU1-63P RNA expression in normal versus tumor tissue (log2 FC = −0.099, t-test p = .015).
This table shows molecular features associated with RNU1-63P in patient tissues and cancer cell lines. In patient samples, RNU1-63P shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set.
